Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Trang M.¹^ORCID,Griffith D. C.²,Bhavnani S. M.¹^ORCID,Loutit J. S.²,Dudley M. N.²,Ambrose P. G.¹,Rubino C. M.¹

Affiliation:

1. Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA

2. Rempex Pharmaceuticals, San Diego, California, USA

Abstract

Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Population pharmacokinetic (PK) models were developed to characterize the time course of meropenem and vaborbactam using pooled data from two phase 1 and two phase 3 studies.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02606-20

Reference45 articles.

1. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

2. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

3. Pfizer. 2019. Meropenem (MERREM IV)® package insert. Pfizer New York NY.

4. Three Decades of β-Lactamase Inhibitors

5. Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients;Scientific Reports;2024-08-20

2. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram‐negative bacterial infections;British Journal of Clinical Pharmacology;2024-06-26

4. Meropenem/Vaborbactam—A Mechanistic Review for Insight into Future Development of Combinational Therapies;Antibiotics;2024-05-21

5. Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients;2024-01-18